17.35
0.34 (2.00%)
| Previous Close | 17.01 |
| Open | 17.25 |
| Volume | 550,870 |
| Avg. Volume (3M) | 1,390,470 |
| Market Cap | 1,603,140,096 |
| Price / Earnings (Forward) | 18.12 |
| Price / Sales | 0.540 |
| Price / Book | 2.62 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -29.43% |
| Operating Margin (TTM) | -3.81% |
| Diluted EPS (TTM) | -8.39 |
| Quarterly Revenue Growth (YOY) | -1.60% |
| Total Debt/Equity (MRQ) | 149.92% |
| Current Ratio (MRQ) | 0.970 |
| Operating Cash Flow (TTM) | 164.20 M |
| Levered Free Cash Flow (TTM) | 310.66 M |
| Return on Assets (TTM) | -1.74% |
| Return on Equity (TTM) | -61.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Fortrea Holdings Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.88 |
|
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 101.90% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Evercore ISI Group, 44.09%) | Buy |
| Median | 18.00 (3.75%) | |
| Low | 13.00 (Mizuho, -25.07%) | Hold |
| Average | 18.50 (6.63%) | |
| Total | 3 Buy, 3 Hold | |
| Avg. Price @ Call | 16.76 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 22 Jan 2026 | 15.00 (-13.54%) | Hold | 17.35 |
| Truist Securities | 08 Jan 2026 | 22.00 (26.80%) | Buy | 17.44 |
| Evercore ISI Group | 06 Jan 2026 | 25.00 (44.09%) | Buy | 17.54 |
| Mizuho | 18 Dec 2025 | 13.00 (-25.07%) | Hold | 16.61 |
| Barclays | 15 Dec 2025 | 15.00 (-13.54%) | Hold | 16.06 |
| 06 Nov 2025 | 10.00 (-42.36%) | Sell | 11.02 | |
| Citigroup | 11 Dec 2025 | 21.00 (21.04%) | Buy | 15.55 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call |
| 09 Jan 2026 | Announcement | Fortrea Announces Updated Presentation Time at Upcoming J.P. Morgan Healthcare Conference |
| 06 Jan 2026 | Announcement | Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference |
| 10 Dec 2025 | Announcement | Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Dec 2025 | Announcement | SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery |
| 25 Nov 2025 | Announcement | Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences |
| 24 Nov 2025 | Announcement | Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand |
| 17 Nov 2025 | Announcement | Fortrea Appoints Agnieszka Gallagher as General Counsel |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |